ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Targeted Delivery of Costimulation Inhibitor to Lymph Nodes Promotes Transplant Tolerance via Fibroblastic Reticular Cells

J. Zhao1, S. Jung1, X. Li1, H. Zhang1, S. Movahedi1, V. Kasinath1, M. Uehara1, J. Azzi1, P. Sage1, S. Tullius1, J. S. Bromberg2, R. Abdi1

1Brigham and Women's Hospital, Boston, MA, 2University of Maryland School of Medicine, Baltimore, MD

Meeting: 2022 American Transplant Congress

Abstract number: 2

Keywords: Fibrosis, Graft acceptance, Lymph node, T cell activation

Topic: Basic Science » Basic Science » 07 - Vascular, Lymphatic, Stromal and Parenchymal Cell Biology

Session Information

Session Name: Plenary Session 1

Session Type: Plenary

Date: Sunday, June 5, 2022

Session Time: 8:25am-9:30am

 Presentation Time: 8:45am-9:00am

Location: Hynes Veterans Auditorium

*Purpose: The lymph node (LN) is the primary site of alloimmunity activation and regulation during transplantation. Fibroblastic reticular cells (FRCs), the prominent cells of the LN stroma, are master arbiters of the LN microenvironment, and they regulate T cell trafficking across high endothelial venules (HEVs) into the LN as well as their positioning alongside dendritic cells. Meca79 mAb recognizes peripheral node addressin (PNAd), a glycoprotein family expressed exclusively by LN-restricted HEVs. We have demonstrated previously that Meca79-conjugated polymeric NPs (Meca79-NPs) enter LNs through HEVs following systemic administration in mice, forming the basis of a LN-targeted drug delivery platform. Here, we hypothesize that LN-targeted nanodelivery of the costimulatory blockade agent anti-CD40L will enhance cardiac allograft tolerance in mice following transplantation, through potentiation of immunoregulatory FRC activity.

*Methods: We transplanted cardiac allografts into CCL19Cre x iDTR mice, in which FRCs can be conditionally ablated, to examine the importance of FRCs to allograft survival. Through intravital microscopy, we tested the interaction between CD11c+ dendritic cells and T cells in the LNs of these mice. Meanwhile, we tested how FRCs alter CD4+ T cell differentiation in vitro. Then, we encapsulated the immune therapeutic anti-CD40L inside Meca79-NP (Meca79-anti-CD40L-NP) and tested its delivery to draining lymph nodes (DLNs) following skin transplantation and its efficacy in prolonging heart allograft survival in mice through intravenous injection.

*Results: FRC depletion in CCL19Cre x iDTR mice abrogated the tolerogenic effect of anti-CD40L treatment following heart transplantation. Intravital microscopy showed that FRCs facilitated the interaction between CD11c+ dendritic cells and T cells in the LN. FRCs also induced the differentiation of CD4+ T cells to Tregs but suppressed their differentiation to effector T cells in vitro. DLNs of cardiac transplant recipients that received Meca79-anti-CD40L-NP contained more regulatory T cells and lower rejection, as signified by smaller immune cell infiltrates, than the soluble anti-CD40L-treated group at 7 days post-transplantation. Finally, combined treatment with Meca79-anti-CD40L-NP and rapamycin resulted in a markedly longer allograft survival than soluble anti-CD40L and rapamycin (mean of 80 days vs. 24 days, respectively, p<0.001).

*Conclusions: These data demonstrate that FRC are the master regulators of the LN microenvironment following transplantation andestablish the efficacy and feasibility of our first-in-class therapeutic approach to promote transplant survival through delivery of costimulation blockade to the LN.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Zhao J, Jung S, Li X, Zhang H, Movahedi S, Kasinath V, Uehara M, Azzi J, Sage P, Tullius S, Bromberg JS, Abdi R. Targeted Delivery of Costimulation Inhibitor to Lymph Nodes Promotes Transplant Tolerance via Fibroblastic Reticular Cells [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/targeted-delivery-of-costimulation-inhibitor-to-lymph-nodes-promotes-transplant-tolerance-via-fibroblastic-reticular-cells/. Accessed May 28, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences